Skip to main content

Table 2 Results of the Kaplan–Meier analysis of progression free and overall survival

From: Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer

 

PFS, months (95% CI)

p value

OS, months (95% CI)

p value

Age

 <64 years

10.3 (8.4–12.2)

0.714

31.9 (11.7–52.1)

0.751

 ≥64 years

10.4 (6.7–14.1)

 

27.1 (5.3–48.8)

 

Sex

 Male

10.6 (7.5–13.6)

0.245

31.9 (12.2–51.6)

0.936

 Female

10.1 (5.8–14.2)

 

25.8 (8.2–43.4)

 

ECOG PS

 0–1

15.1 (9.2–20.9)

0.001

63.5 (30.8–96.2)

0.001

 ≥2

8.2 (3.4–12.9)

 

15.1 (10.7–19.5)

 

Disease free interval

 <1 year

9.2 (5.1–13.3)

0.063

22.0 (0–50.5)

0.131

 ≥1 year

13.2 (9.2–17.2)

 

41.1 (16.1–65.9)

 

Lung metastasis

 Yes

6.9 (2.0–11.7)

0.139

27.1 (18.4–35.7)

0.722

 No

13.2 (6.7–19.7)

 

37.2 (12.7–61.7)

 

Liver metastasis

 Yes

4.3 (0.0–11.1)

0.680

14.4 (0–49.1)

0.388

 No

10.4 (8.9–12.0)

 

31.9 (15.8–48.0)

 

Lymph node metastasis

 Yes

10.3 (7.6–13.0)

0.180

14.4 (9.1–19.7)

0.037

 No

10.4 (7.9–12.9)

 

40.3 (28.4–52.1)

 

Bone metastasis

 Yes

10.1 (6.6–13.4)

0.309

18.2 (13.3–23.1)

0.021

 No

10.6 (8.8–12.3)

 

40.3 (20.2–60.3)

 

Brain metastasis

 Yes

3.2 (2.1–4.3)

0.001

5.9 (0.1–11.7)

0.012

 No

10.6 (9.0–12.1)

 

37.2 (17.1–57.3)

 

Metastasis at other site

 Yes

9.1 (5.8–12.5)

0.620

27.1 (10.7–43.4)

0.384

 No

10.4 (8.4–12.4)

 

63.5 (6.2–120.8)

 

Number of metastatic site

 1

13.2 (8.7–17.7)

0.001

40.3 (24.7–55.8)

0.007

 ≥2

5.0 (0.4–9.6)

 

13.7 (9.3–18.1)

 

Previous nephrectomy

 Yes

10.5 (6.0–15.1)

0.522

37.2 (19.1–55.3)

0.113

 No

10.3 (7.1–13.5)

 

18.2 (6.6–29.7)

 

TKI regimen

 Sunitinib

10.1 (7.6–12.5)

0.664

37.2 (15.9–58.5)

0.786

 Pazopanib

10.6 (10.1–11.1)

 

25.8 (10.2–41.3)

 

Neutrophil–lymphocyte ratio

 ≤3.6

16.3 (10.4–22.2)

0.001

63.5 (37.4–89.6)

0.001

 >3.6

5.0 (0.7–9.3)

 

17.0 (12.4–21.6)

 

Platelet–lymphocyte ratio

 ≤150

18.1 (6.2–29.9)

0.001

50.5 (28.5–72.4)

0.001

 >150

4.4 (3.5–5.3)

 

13.7 (7.8–19.6)

 

Hemoglobin

 <12 (g/dL)

7.2 (0.3–13.9)

0.237

25.8 (8.3–43.2)

0.252

 ≥12 (g/dL)

11.7 (8.6–14.8)

 

37.2 (17.5–56.8)

 

Corrected calcium

 <10 (mg/dL)

10.3 (8.7–11.9)

0.652

31.9 (14.4–49.4)

0.206

 ≥10 (mg/dL)

Not reached

 

Not reached